BIO International Convention
- Asees Kaur
- Jun 16
- 2 min read
VoxCell BioInnovation is proud to attend the BIO International Convention 2025, held at the Boston Convention & Exhibition Center, the world’s largest biotechnology gathering, uniting over 18,500 global leaders across biotech, pharma, academia, government, and investment.
At this year’s convention, VoxCell showcased our 3D bioprinted, vascularized tissue models, a platform that brings unprecedented realism and predictive power to preclinical drug testing. In 2024, VoxCell was selected to participate in BIO’s prestigious Start-Up Stadium, a Dragon’s Den–style pitch competition featuring the most promising early-stage biotech companies. With just 5 minutes to pitch and 5 minutes of rapid-fire Q&A, we showcased our proprietary bioprinting technology and demonstrated how our vascularized tissue models are reshaping the landscape of drug discovery. As we continue to advance our mission of improving cancer drug development, BIO provides the ideal stage to share our innovations, build strategic partnerships, and amplify our impact within the global biotech ecosystem.
About the BIO International Convention
The BIO International Convention is the most comprehensive event in the biotechnology industry, representing the full breadth of the biotech ecosystem. With 20,000 attendees from around the globe, it connects startups, public pharma companies, academic researchers, non-profits, government agencies, investors, and business development leaders. From therapeutic innovation to cutting-edge diagnostics and manufacturing, BIO sets the stage for the future of global healthcare.
About VoxCell BioInnovation
VoxCell BioInnovation is a leading provider of next-generation in vitro models, powered by our 3D bioprinted, vascularized tissue technology. Our ready-to-perfuse models closely replicate human biology with in vivo–like microvascular networks, enabling nutrient and oxygen delivery, systemic drug distribution, and more predictive therapeutic responses. VoxCell’s end-to-end solution offers researchers and pharmaceutical companies a scalable, ethical alternative to animal testing. Our mission is to reduce reliance on animal models, accelerate preclinical development, and advance more effective therapies for patients.
Want to learn more or collaborate?
Visit our website, connect with us on LinkedIn, or email us at hello@voxcellbio.com.
